HISTORY
BREONICS is a private research and discovery company located in Albany, New York. Organized in 1996, the company has developed a new and innovative technology Exsanguinous Metabolic Support (EMS) which enables the continued oxidative metabolism and function of organs and tissues while isolated from the rest of the human body. EMS is the first technology that can be used to intervene after cardiac arrest and repair ischemically damaged kidneys for transplantation. This unique ability of EMS changes today’s limitation of recovering cadaveric kidneys from within minutes of death to a window of several hours postmortem significantly broadening the criteria for organ donation to include those patients who are declared dead from cardiac arrest at an accident scene, in the ER, or in the hospital.
Company
September 01, 2010
BREONICS announces the award of a NIH $2.9 Million RC3 BRDG-SPAN SBIR Grant to begin Clinical Development of EMS to Provide more cadaveric kidneys for transplant. More...
August 01, 2010
BREONICS announces $200K second year R43 SBIR Funding for: “The Potential to Immunocloak Renal Allografts”. More...
Investor Relations
BREONICS is currently a privately-held company. For more information please contact breonicsinvest@breonics.com